Choosing Blood Biomarkers for Geroscience Trials: The TAME Framework

Key idea

A workgroup from the Targeting Aging with Metformin (TAME) initiative outlines a practical way to select blood-based biomarkers for geroscience-guided clinical trials. Geroscience targets aging biology to extend healthspan, so trials need biomarkers to detect meaningful biological change before clinical outcomes appear.

Educational content only; not medical advice.

Why this matters

• Aging outcomes (disability, multimorbidity) unfold over years, making trials long and expensive.
• Blood tests are accessible and standardizable, enabling repeat sampling across sites.
• Good biomarkers can link an intervention to aging mechanisms, guide dosing and timing, and help select participants.

What the report proposes

This is a framework, not a treatment trial. It sets criteria and steps for picking and using biomarkers in geroscience research, using the TAME program as a motivating example. No clinical effects are claimed.

1) Define the context of use

• Diagnostic: indicates a current state related to aging biology.
• Prognostic: estimates future risk of adverse outcomes.
• Predictive: identifies who is more likely to respond to an intervention.
• Pharmacodynamic: shows a biological response after treatment.
• Surrogate endpoint: a biomarker used in place of a clinical outcome; in aging, surrogates are not yet validated and must be used cautiously.

A clear context guides study design, timing of blood draws, and analysis.

2) Require analytical validity

Analytical validity means the test measures the biomarker accurately and reproducibly.

• Test–retest reliability: agreement across repeat measures in the same person.
• Intra-individual variability: normal ups and downs over time within a person.
• Batch effects: non-biological shifts from different reagent lots, instruments, or labs; use standards and cross-batch controls.
• Dynamic range and detection limits: the assay must measure values where the biology actually occurs.
• Pre-analytics: specify and control draw conditions, processing, storage, and freeze–thaw cycles.

3) Link to aging biology

Choose markers tied to known aging pathways (e.g., inflammation, energy metabolism, cellular stress, cellular senescence—aging cells that stop dividing and release signals). Biological plausibility strengthens interpretation but does not prove clinical benefit.

4) Sensitivity and time course

• How quickly and how much does the marker change after intervention?
• Do short-term shifts relate to longer-term risk?
• Use serial sampling; single time points can mislead because of biological noise.

5) Use panels and composite indices when appropriate

No single marker captures the complexity of aging. Panels or composite scores can improve signal-to-noise and robustness. They require transparent construction, independent validation, and safeguards against overfitting.

6) Ensure real-world feasibility

• Cost and availability of assays.
• Scalability for repeated measures in large trials.
• Standardized protocols across centers.
• Biobanking to allow future retesting with improved methods.

7) Bridge biomarkers to clinical outcomes

Even if the near-term goal is mechanistic insight, plan connections to outcomes: long-term follow-up, linkage to cohorts and registries, and analyses that relate biomarker change to disease and function over time.

Definitions

• Biomarker: a measurable signal of a biological process, disease, or response to therapy.
• Geroscience: study of aging biology and its link to age-related diseases.
• Surrogate endpoint: a biomarker used instead of a clinical endpoint; it needs rigorous validation.
• Test–retest reliability: stability of a measure when repeated in the same person.
• Batch effects: non-biological differences between assay runs, reagent lots, or equipment.

What this means in practice

For researchers:

• Pre-specify context of use and analysis plans in the protocol.
• Standardize pre-analytics and quality control; include cross-batch reference materials.
• Budget for repeat measures, blinded duplicates, and inter-lab comparisons.
• Favor validated panels over single markers when possible; seek independent replication.
• Bank samples for retesting and evolving technologies.

For readers and clinicians:

• A change in one biomarker does not prove slowed aging.
• Stronger evidence comes from consistent shifts across marker profiles that align with biology and relate to outcomes.
• Interpret tests with a clinician and consider the broader health context.

Evidence quality

Framework and expert consensus (2018). Not a randomized trial or meta-analysis. The authors provide principles and selection criteria; they do not claim clinical effects for any intervention.

Limitations and open questions

• No universally validated surrogate endpoint for "aging" exists.
• Cross-platform and cross-lab variation remains a barrier; harmonization is needed.
• Biomarkers estimate risk and trends, not destinies; predictive power is limited.
• Focus is on blood; other domains (imaging, functional tests, tissues) also matter but are outside scope.

Practical takeaways

• Start with a clear context of use.
• Demand analytical validity and control batch effects.
• Use serial measurements and plan for within-person variability.
• Consider validated panels; pursue independent replication.
• Link short-term biomarker changes to longer-term clinical data whenever possible.
• Pre-register plans and publish neutral or negative findings.

This article is for education only and is not medical advice. Decisions about testing or treatment should be made with a clinician.

Sources

• Original publication: https://pmc.ncbi.nlm.nih.gov/articles/PMC6294728/
• DOI / PubMed: 10.1007/s11357-018-0042-y